Title: Atipamezole
CAS Registry Number: 104054-27-5
CAS Name: 4-(2-Ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole
Additional Names: 4(5)-(2-ethyl-2-indanyl)imidazole
Molecular Formula: C14H16N2
Molecular Weight: 212.29
Percent Composition: C 79.21%, H 7.60%, N 13.20%
Literature References: Specific a2-adrenoceptor antagonist. Prepn: A. J. Karjalainen et al., EP 183492; eidem, US 4689339 (1986, 1987 both to Farmos). Behavioral and neurochemical effects: H. Scheinin et al., Eur. J. Pharmacol. 151, 35 (1988). Pharmacodynamics and pharmacokinetics: X. Fargetton, T. Vähä-Vahe, Tijdschr. Diergeneeskd 114, Suppl. 1, 91S (1989). Binding study in comparison with yohimbine, q.v.: R. Virtanen et al., Arch. Int. Pharmacodyn. 297, 190 (1989). Attenuation of ethanol effects in mice: M. J. Durcan et al., Alcohol 6, 189 (1989). Preliminary report as detomidine, q.v., antagonist in horses: L. Nilsfors, C. Kvart, Acta Vet. Scand. 82, 121 (1986). Use as medetomidine, q.v., antagonist in zoo animals: H. Jalanka, ibid. 85, 193 (1989).
Derivative Type: Hydrochloride
CAS Registry Number: 104075-48-1
Manufacturers' Codes: MPV-1248
Trademarks: Antisedan (Pfizer)
Molecular Formula: C14H16N2.HCl
Molecular Weight: 248.75
Percent Composition: C 67.60%, H 6.89%, N 11.26%, Cl 14.25%
Properties: Crystals from dry HCl in ethyl acetate, mp 211-215°. LD50 in male, female rats (mg/kg): >50, 44 s.c. (Scheinin).
Melting point: mp 211-215°
Toxicity data: LD50 in male, female rats (mg/kg): >50, 44 s.c. (Scheinin)
Therap-Cat-Vet: Antidote to a2-adrenoceptor induced sedation.
Atisine Atomoxetine Atosiban Atovaquone Atractyloside

Systematic (IUPAC) name
Clinical data
AHFS/ International Drug Names
Legal status Veterinary use only
CAS number 104054-27-5 N
ATCvet code QV03AB90
PubChem CID 71310
ChemSpider 64427 YesY
KEGG D03002 YesY
Chemical data
Formula C14H16N2 
Mol. mass 212.290 g/mol
 N (what is this?)  (verify)

Atipamezole (brand name Antisedan, Pfizer) is a synthetic alpha2-adrenergic antagonist, indicated for the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs.[1] It has also been researched in humans as a potential anti-Parkinsonian drug.[2]